Please login to the form below

Not currently logged in

First wave of CCGs authorised

New NHS groups will serve 10 million people

Proposed CCG boundaries
Some of the proposed CCG boundaries

The UK government have given the green light to the first wave of clinical commissioning groups (CCGs), authorising 34 of the new organisations to plan and commission health services from April 2013.

CCGs were set up under the Health and Social Care Act and will next year replace Primary Care Trusts (PCTs) by handing responsibility for hospital, community health and mental health services to local clinicians.

In doing so the changes will see CCGs take control of up to £65bn of the £95bn NHS Commissioning Board budget from April, 1 2013.

Sir David Nicholson, the NHS Commissioning Board's chief executive, said: “The creation of CCGs is a great opportunity for the NHS that will have real benefits for patients.

“In future, the vast majority of decisions about how we use the public's money will be made in the community by the clinicians who are closest to the needs of the people they look after.

The reforms will ultimately see 211 CCGs, each made up of the GP practices in their area, replace the 152 primary care trusts that currently commission healthcare services.

Dame Barbara Hakin, the NHS Commissioning Board's national director of commissioning development, said: “This is a step-change to a clinically-led NHS that is focused on delivering improved health outcomes, quality, innovation and public participation.

“We expect this to bring real benefits to patients as these new organisations begin to realise their potential. Many CCGs have already begun to make a difference by taking early responsibility for planning services.”

The NHS Commissioning Board, which is responsible for ensuring CCGs meet and maintain standards, authorised eight of the 34 CCGs in the first wave with no conditions. But although it passed the remaining 26 CCGs it said they “need to continue developing” if they are to meet all the criteria. Together these groups will serve 10 million people.

The review of one of the new CCGs – NHS Liverpool CCG – has been deferred in order to assess that the significant late changes it made to its commissioning arrangements are enough for it to be authorised.

CCGs are assessed on areas such as their leadership, engagement with patients and clinicians, financial stability and the quality of their relationships with important partners.

The NHS Commissioning Board plans to complete the authorisation process for the remaining 177 CCGs in a further three waves, publishing the results in January, February and March 2013.

The 34 authorised CCGs are:

North of England
NHS Bassetlaw CCG
NHS Blackpool CCG
NHS Calderdale CCG
NHS Cumbria CCG
NHS East Riding
NHS North East Lincolnshire CCG
NHS Oldham CCG
NHS Rotherham CCG
NHS Wakefield CCG
NHS Warrington CCG
NHS West Cheshire CCG

Midlands and the East
NHS Dudley CCG
NHS East and North Herts CCG
NHS East Leicestershire & Rutland CCG
NHS Great Yarmouth and Waveney CCG
NHS Leicester City CCG
NHS North Staffordshire CCG
NHS Sandwell and West Birmingham CCG
NHS Shropshire CCG
NHS Stoke on Trent CCG
NHS West Leicestershire CCG

South of England
NHS Bedfordshire CCG
NHS Gloucestershire CCG
NHS Kernow CCG
NHS Newbury and District CCG
NHS North and West Reading
NHS Oxfordshire CCG
NHS Portsmouth CCG
NHS Somerset CCG
NHS South Reading CCG
NHS Wokingham CCG

NHS Islington CCG
NHS Kingston CCG
NHS Wandsworth CCG

12th December 2012

From: Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...